Gold nanoparticles and radiation therapy for advanced melanoma
Treatments studied
Part of Cancer clinical trials.
This study tests a new treatment combining gold nanoparticles (Au-TMP), radiation therapy, and an immune-boosting drug (anti-PD-1) for advanced melanoma that cannot be surgically removed. The goal is to help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and in good enough health to tolerate treatment (ECOG score 0–1, meaning you can do most daily activities)
- You have advanced melanoma (Stage III or IV) that has not been treated with systemic therapy before, though prior adjuvant or neoadjuvant therapy is okay if finished 3+ weeks ago
- You have at least one tumor lesion that can be injected with the gold nanoparticles and treated with radiation (in skin, fat layer, lymph nodes, or accessible internal organs)
- Your blood cell counts, kidney function, liver function, and heart function are adequate based on recent lab tests
- You have never received anti-PD-1 or anti-PD-L1 immunotherapy before
- You are willing to use effective contraception during the study and for 12 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy made from your own tumor-fighting cells (TILs) for advanced melanoma that hasn't responded to other treatments. It aims to shrink tumors by re-infusing these boosted cells back into your body.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests a new therapy that uses tiny gold particles to heat and destroy melanoma tumors on the skin or just under the skin. It is for people whose melanoma has spread and has not responded to standard treatments.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.